Trial Profile
Phase II Study of Trastuzumab Biosimilar (Herzuma) Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer Who Progressed After 2 or More HER-2 Directed Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms KM-10A
- 16 Feb 2021 Planned number of patients changed from 62 to 15.
- 16 Feb 2021 Status changed from not yet recruiting to recruiting.
- 16 Oct 2018 New trial record